Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward
You may also be interested in...
As Clinical Trials Boom In India, Patient Recruitment Firm D. Anderson Plans To Establish Direct Presence
MUMBAI - U.S. based D. Anderson & Co, a provider of global patient recruitment and retention services for clinical trials, is planning to establish a direct presence in India
As Clinical Trials Boom In India, Patient Recruitment Firm D. Anderson Plans To Establish Direct Presence
MUMBAI - U.S. based D. Anderson & Co, a provider of global patient recruitment and retention services for clinical trials, is planning to establish a direct presence in India
Drug Controller General Of India, Surinder Singh, On India’s Regulatory Overhaul: An Interview With PharmAsia News
Singh recounts steps toward Indian first-in-human drug trials.